What is a stock summary page? Click here for an overview.
Business Description
GSK PLC
NAICS : 325412
SIC : 2834
ISIN : ARDEUT110483
Share Class Description:
BUE:GSK: CedearDescription
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 1.24 | |||||
| Debt-to-EBITDA | 2.55 | |||||
| Interest Coverage | 8.66 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.59 | |||||
| Beneish M-Score | -2.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.5 | |||||
| 3-Year EBITDA Growth Rate | 0.2 | |||||
| 3-Year EPS without NRI Growth Rate | -1.1 | |||||
| 3-Year FCF Growth Rate | -13 | |||||
| 3-Year Book Growth Rate | -3.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 27.24 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 4.66 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.59 | |||||
| 9-Day RSI | 43.8 | |||||
| 14-Day RSI | 49.35 | |||||
| 3-1 Month Momentum % | 16.01 | |||||
| 6-1 Month Momentum % | -3.98 | |||||
| 12-1 Month Momentum % | 6.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.78 | |||||
| Quick Ratio | 0.52 | |||||
| Cash Ratio | 0.17 | |||||
| Days Inventory | 231.12 | |||||
| Days Sales Outstanding | 76.64 | |||||
| Days Payable | 406.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.18 | |||||
| Dividend Payout Ratio | 0.65 | |||||
| 3-Year Dividend Growth Rate | -15.2 | |||||
| Forward Dividend Yield % | 3.48 | |||||
| 5-Year Yield-on-Cost % | 1.67 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | 10.12 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.16 | |||||
| Operating Margin % | 17.66 | |||||
| Net Margin % | 8.21 | |||||
| FCF Margin % | 11.69 | |||||
| ROE % | 18.6 | |||||
| ROA % | 4.39 | |||||
| ROIC % | 9.18 | |||||
| 3-Year ROIIC % | 0.33 | |||||
| ROC (Joel Greenblatt) % | 41.63 | |||||
| ROCE % | 10.91 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.68 | |||||
| Forward PE Ratio | 10.69 | |||||
| PE Ratio without NRI | 15.13 | |||||
| Shiller PE Ratio | 9.23 | |||||
| Price-to-Owner-Earnings | 10.33 | |||||
| PS Ratio | 1.87 | |||||
| PB Ratio | 4.23 | |||||
| Price-to-Free-Cash-Flow | 16.43 | |||||
| Price-to-Operating-Cash-Flow | 8.95 | |||||
| EV-to-EBIT | 17.07 | |||||
| EV-to-Forward-EBIT | 6.85 | |||||
| EV-to-EBITDA | 10.54 | |||||
| EV-to-Forward-EBITDA | 6.42 | |||||
| EV-to-Revenue | 2.24 | |||||
| EV-to-Forward-Revenue | 2.16 | |||||
| EV-to-FCF | 19.67 | |||||
| Price-to-GF-Value | 0.98 | |||||
| Price-to-Projected-FCF | 0.93 | |||||
| Price-to-Median-PS-Value | 0.88 | |||||
| Earnings Yield (Greenblatt) % | 5.86 | |||||
| FCF Yield % | 6.2 | |||||
| Forward Rate of Return (Yacktman) % | 4.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GSK PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 37,302,188.74 | ||
| EPS (TTM) (ARS) | 353.35 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 1.32 | ||
| 3-Year Sortino Ratio | 2.86 | ||
| Volatility % | 41.01 | ||
| 14-Day RSI | 49.35 | ||
| 14-Day ATR (ARS) | 288.506994 | ||
| 20-Day SMA (ARS) | 12488.75 | ||
| 12-1 Month Momentum % | 6.15 | ||
| 52-Week Range (ARS) | 9110 - 14400 | ||
| Shares Outstanding (Mil) | 8,122.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GSK PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GSK PLC Stock Events
| Event | Date | Price (ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
GSK PLC Frequently Asked Questions
What is GSK PLC(BUE:GSK)'s stock price today?
The current price of BUE:GSK is ARS12175.00. The 52 week high of BUE:GSK is ARS14400.00 and 52 week low is ARS9110.00.
When is next earnings date of GSK PLC(BUE:GSK)?
The next earnings date of GSK PLC(BUE:GSK) is 2025-04-30.
Does GSK PLC(BUE:GSK) pay dividends? If so, how much?
The Dividend Yield %  of GSK PLC(BUE:GSK) is 3.18% (As of Today), Highest Dividend Payout Ratio of GSK PLC(BUE:GSK) was 2.39. The lowest was 0.43. And the median was 1.02. The  Forward Dividend Yield % of GSK PLC(BUE:GSK) is 3.48%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers